Related Experiment Video

Updated: Sep 21, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

Bempedoic acid: a novel oral LDL-cholesterol lowering agent

Ishwarlal Jialal1, Neeraj Ramakrishnan2

  • 1VA Medical Center Mather, CA, USA.

International Journal of Physiology, Pathophysiology and Pharmacology
|May 27, 2022
PubMed

Insights

Bempedoic Acid (BA), a new ATP-citrate lyase inhibitor, effectively lowers LDL-cholesterol and apoB levels, offering a potential alternative for patients intolerant to statins. Further outcomes trials are needed to confirm its role in managing atherosclerotic cardiovascular disease.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Elevated LDL-cholesterol is a major risk factor for atherosclerotic cardiovascular disease (ASCVD).
  • Statins are the primary pharmacotherapy for high-risk patients, but some may be statin-intolerant.

Purpose of the Study:

  • To evaluate the efficacy and role of Bempedoic Acid (BA), a novel ATP-citrate lyase inhibitor, in managing elevated LDL-cholesterol and its impact on ASCVD risk.
  • To assess BA's effectiveness, particularly in combination with ezetimibe, for statin-intolerant patients.

Main Methods:

  • Review of clinical trial data, including the CLEAR trials, assessing Bempedoic Acid's effects on lipid profiles and other biomarkers.
  • Analysis of BA's efficacy compared to placebo and its potential benefits in specific patient populations.

Main Results:

  • Bempedoic Acid demonstrated superiority over placebo in reducing LDL-cholesterol (LDL-C).
  • BA also effectively lowered apoB and hsCRP levels.
  • BA showed particular efficacy when combined with ezetimibe, especially in statin-intolerant individuals.

Conclusions:

  • Bempedoic Acid is a promising agent for LDL-C reduction, offering an alternative for statin-intolerant patients.
  • Potential side effects include modest LDL-C reduction, decreased HDL-C, hyperuricemia, and elevated creatinine.
  • The ongoing Outcomes trial will be crucial in establishing BA's definitive role in ASCVD event management.

Keywords:
C-reactive proteinHyperlipidemiaLDL-cholesterolbempedoic acidstatin-intoleranceuric acid

More Related Videos

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.2K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.6K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
900
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
665
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
383
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
47
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
872
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
852